Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Exit

Woodford loses touch with Ultrahaptics
19th August 2019
Callum Cyrus
Woodford Investment Management has reportedly reaped $24.1m on its 20% stake in University of Bristol's Ultrahaptics.
GraphPad scribbles down SnapGene
14th August 2019
Callum Cyrus
SnapGene, a molecular biology documentation spinout of UChicago, has been acquired by scientific data analysis tool provider GraphPad Software.
Freiburg celebrates Cytena exit
9th August 2019
Callum Cyrus
Cell culturing technology Cellink has bought University of Freiburg's single-cell dispensing spinout Cytena for almost $34m.
Aquinox combines with Washington’s Neoleukin
7th August 2019
Callum Cyrus
UW-founded cancer immunotherapy developer Neoleukin Therapeutics will merge with Aquinox in an all-share deal giving the spinout's shareholders roughly 38.6% equity in the new company.
Ford receives Quantum Signal
1st August 2019
Callum Cyrus
Quantum Signal has been bought by Ford after two decades of quietly producing technologies for robotic applications including autonomous driving.
VMware vies for Uhana acquisition
31st July 2019
Jack Hammond
Telstra Ventures looks set to exit Stanford spinout Uhana in an an acquisition of undisclosed size by VMware.
Microsoft tames BlueTalon for acquisition
31st July 2019
Callum Cyrus
Microsoft has bought big data access control software developer BlueTalon, which had raised approximately $26m from investors including Stanford-StartX Fund.
Kinectrics connects with Gnosys Global
30th July 2019
Callum Cyrus
Kinectrics has bought University of Surrey's Gnosys Global in a bid to extend its global presence and unlock the potential of a combined product portfolio.

Other News

Woodford trims Mercia stake
30th July 2019
Callum Cyrus
Woodford Investment Management has reduced its holding in Mercia Asset Management amid reports its Patient Capital Trust could move to replace Neil Woodford as manager.
TikTok swings by to collect Jukedeck
24th July 2019
Callum Cyrus
University of Cambridge's automated music production app developer Jukedeck has been picked up by internet technology firm Bytedance's TikTok.
Daily deal net: July 18, 2019
18th July 2019
Callum Cyrus
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Woodford prepares biotech clearance
18th July 2019
Callum Cyrus
Woodford Investment Management will auction unlisted biotech investments which include Oxford Nanopore in a process that could take three months to reach its conclusion.
Amal advances to $365m acquisition
16th July 2019
Thierry Heles
Boehringer Ingelheim will pay a total of up to $365m to acquire its venture fund's portfolio company Amal Therapeutics, an immunotherapy spinout of University of Geneva.
Roche’s Spark acquisition hits delay
9th July 2019
Callum Cyrus
The deadline for Roche’s $4.3bn purchase of CHOP's gene therapy developer Spark has been postponed until April 2020 amid regulatory scrutiny and pending lawsuits.

Editor's Picks

Otsuka takes up Veryan’s acquisition offer
17th December 2018
Callum Cyrus
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
5th November 2018
Thierry Heles
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
20th August 2018
Thierry Heles
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
2nd October 2017
Thierry Heles
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
© 2019 Mawsonia Ltd. All rights reserved.
test reg

Login

Forgot password?

Not yet subscribed?

See your subscription offers here